- Trial phase
- Approved (for CMV prophylaxis in HSCT). Phase 2 completed for lung transplant indication (NCT05041426).
- Time to market
- Already approved and commercially available (FDA approval November 8, 2017). Additional indications may be pursued but no near-term timeline is defined.
- Why 2/10
- No upcoming PDUFA, pivotal readout, or binary catalyst for PREVYMIS in the next ~12 months. The drug was approved in November 2017 and is a mature commercial product within Merck's vast portfolio. ImpactScore is 2 because the drug carries no near-term defined catalyst to move MRK shares and is a very small part of a mega-cap diversified pharma company.
PREVYMIS is already approved and commercialized; there is no upcoming PDUFA, pivotal readout, or binary catalyst for this drug in the next 12 months. For MRK investors, PREVYMIS is a negligible standalone consideration. Focus instead on Merck's upcoming KEYTRUDA PDUFA dates (September 21, 2026) and the ifinatamab deruxtecan PDUFA (October 10, 2026) for material catalysts.
Price Chart
Executive Summary
PREVYMIS (letermovir) is an FDA-approved antiviral drug from Merck & Co. (MRK) for preventing cytomegalovirus (CMV) infection in adult stem-cell transplant recipients. Approved in November 2017, it is a marketed commercial product with no pending regulatory decisions. As one of many products in Merck's massive, diversified portfolio (dominated by KEYTRUDA), PREVYMIS is not a material stock-moving catalyst for MRK, the stock's value is driven by the broader pipeline including upcoming KEYTRUDA label-expansion PDUFA dates and other high-impact assets.
How It Works
PREVYMIS is an antiviral medication that blocks CMV (a common herpes-type virus) from replicating by interfering with the virus's ability to package its DNA into new virus particles. It works differently from older CMV drugs (like ganciclovir) and is less toxic to bone marrow, which is important for transplant patients whose marrow is already stressed.
Trial Status
PREVYMIS was approved by the FDA on November 8, 2017 for prophylaxis of CMV infection in adult CMV-seropositive allogeneic HSCT recipients. An investigator-sponsored Phase 2 trial (NCT05041426) studying letermovir for CMV prevention after lung transplantation completed in March 2025 with results available.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PREVYMIS-specific catalysts identified. For MRK broadly: KEYTRUDA sBLA PDUFA (Sept 21, 2026), WELIREG sNDA PDUFA (Oct 4, 2026), ifinatamab deruxtecan sBLA PDUFA (Oct 10, 2026).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report